Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$66.33 USD
-1.03 (-1.53%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $66.54 +0.21 (0.32%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth F Momentum F VGM
Company Summary
Edwards Lifesciences Corporation, headquartered in Irvine, CA, deals in products and technologies aimed at treating advanced cardiovascular diseases, especially structural heart disease in critically ill patients. The company is the world’s leading manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve.
Edwards is also a leading player in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. Its products and technologies are grouped into four main areas:
Transcatheter Aortic Valve Replacement (TAVR):
Company Summary
Edwards Lifesciences Corporation, headquartered in Irvine, CA, deals in products and technologies aimed at treating advanced cardiovascular diseases, especially structural heart disease in critically ill patients. The company is the world’s leading manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve.
Edwards is also a leading player in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. Its products and technologies are grouped into four main areas:
Transcatheter Aortic Valve Replacement (TAVR): Comprised 64.6% of total revenues in 2023, 10.3% growth from 2022. The segment includes the SAPIEN family of valves used to treat heart valve diseases using catheter-based approaches for patients who have severe symptomatic aortic stenosis (AS) and certain patients with congenital heart disease.
Surgical Structural Heart (16.6%; up 11.9%): This primarily comprises tissue heart valves and heart valve repair products for the surgical repair or replacement of a patient's heart valve. The portfolio also includes a diverse line of products used during minimally invasive surgical procedures and cannulae, embolic protection devices, and other products used during cardiopulmonary bypass.
Critical Care (15.5%, up 8.5%): The portfolio includes pulmonary artery catheters, disposable pressure transducers, and advanced monitoring systems. The portfolio also includes a line of balloon catheter-based products, surgical clips, and inserts. Compatible with its portfolio of sensors and catheters, the HemoSphere monitoring platform displays valuable physiological information. Edwards’ latest algorithm, Acumen Assisted Fluid Management software, provides patient-specific fluid suggestions to help keep patients in an optimal range during surgery.
Transcatheter Mitral and Tricuspid Therapies (TMTT) (3.3%, up 70.2%): This consists of the PASCAL PRECISION and the Cardioband transcatheter valve repair systems for mitral and tricuspid valve repair, which are commercially available in Europe. Presently, the system is commercially available in the United States and Japan for for degenerative mitral regurgitation patients.
General Information
Edwards Lifesciences Corporation
ONE EDWARDS WAY
IRVINE, CA 92614
Phone: 949-250-2500
Fax: 949-250-2525
Email: investor_relations@edwards.com
Industry | Medical - Instruments |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 10/23/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 0.68 |
Current Year EPS Consensus Estimate | 2.71 |
Estimated Long-Term EPS Growth Rate | 8.90 |
Exp Earnings Date | 10/23/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 67.36 |
52 Week High | 96.12 |
52 Week Low | 58.93 |
Beta | 1.13 |
20 Day Moving Average | 6,872,293.50 |
Target Price Consensus | 76.26 |
4 Week | -2.02 |
12 Week | -25.36 |
YTD | -11.66 |
4 Week | -3.76 |
12 Week | -28.54 |
YTD | -26.32 |
Shares Outstanding (millions) | 602.40 |
Market Capitalization (millions) | 40,577.66 |
Short Ratio | NA |
Last Split Date | 6/1/2020 |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | 0.00 |
Change in Payout Ratio | 0.00 |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 24.83 |
Trailing 12 Months | 26.01 |
PEG Ratio | 2.80 |
vs. Previous Year | 6.06% |
vs. Previous Quarter | 6.06% |
vs. Previous Year | -9.43% |
vs. Previous Quarter | -13.28% |
Price/Book | 5.41 |
Price/Cash Flow | 24.38 |
Price / Sales | 6.76 |
6/30/24 | 22.35 |
3/31/24 | 22.86 |
12/31/23 | 23.56 |
6/30/24 | 16.31 |
3/31/24 | 16.52 |
12/31/23 | 16.81 |
6/30/24 | 3.71 |
3/31/24 | 3.75 |
12/31/23 | 3.38 |
6/30/24 | 2.87 |
3/31/24 | 2.67 |
12/31/23 | 2.40 |
6/30/24 | 26.21 |
3/31/24 | 25.20 |
12/31/23 | 25.46 |
6/30/24 | 24.55 |
3/31/24 | 23.01 |
12/31/23 | 23.35 |
6/30/24 | 28.68 |
3/31/24 | 26.19 |
12/31/23 | 26.61 |
6/30/24 | 12.46 |
3/31/24 | 11.93 |
12/31/23 | 11.08 |
6/30/24 | 1.32 |
3/31/24 | 1.31 |
12/31/23 | 1.35 |
6/30/24 | 0.08 |
3/31/24 | 0.08 |
12/31/23 | 0.09 |
6/30/24 | 7.37 |
3/31/24 | 7.67 |
12/31/23 | 8.16 |